The Hematopoietic Cell-Specific Rho GTPase Inhibitor ARHGDIB/D4GDI Limits HIV Type 1 Replication
Tadashi Watanabe(Aichi Medical University), Jun Komano(National Institute of Infectious Diseases), Kei Sato(University of Tokyo Hospital), Reiko Ichikawa(National Institute of Infectious Diseases), Emiko Urano(Unknown), Hirotaka Ebina(The University of Osaka), Naoko Misawa(National Institute of Infectious Diseases), Makiko Hamatake(National Institute of Infectious Diseases), Kosuke Miyauchi(AIDS United), Yoshio Koyanagi(Daido Steel (Japan))
Cited by 26
Related Papers
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
|Cell Reports|2020|438
CRTAM determines the CD4+ cytotoxic T lymphocyte lineage
|The Journal of Experimental Medicine|2015|208